Aim: Chemotherapy-induced nausea and vomiting (CINV) is one of the most frequently encountered side effects of cancer treatment. Severe CINV can lead patients to refuse chemotherapy, which ultimately affects cancer outcomes. The development of fairly new antiemetic agents, 5-hydroxytryptamine-3 receptor antagonists, palonosetron and neurokinin-1 receptor antagonists and aprepitant has reduced the risk and incidence of CINV. In this study, we assessed the efficacy of aprepitant plus palonosetron against palonosetron for CINV in patients receiving moderately emetic cancer chemotherapy (paclitaxel and carboplatin combination [TC] therapy).
Methods: Between November 2010 and March 2014, 78 patients with gynecological cancer treated with TC therapy were randomized into two groups: an aprepitant group (administered aprepitant, dexamethasone and palonosetron) and a control group (administered dexamethasone and palonosetron). The primary study endpoint was complete response, defined as the complete absence of emetic events in the delayed phase.
Results: The complete response rate in the delayed phase differed significantly between the two groups, with 82% in the aprepitant group and 97% in the control group (P = 0.025).
Conclusion: The combination of aprepitant and palonosetron appears to be of greater efficacy than palonosetron alone for the prevention of delayed-phase CINV induced by TC therapy.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/jog.13378 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Comparative Efficacy of Novel Versus Traditional Antiemetic Agents in Preventing Chemotherapy-Induced Nausea and Vomiting With Moderate or Highly Emetogenic Chemotherapy: A Systematic Review.
Cureus
October 2024
Department of Internal Medicine, Allama Iqbal Medical College, Lahore, PAK.
Article Synopsis
- The review analyzes the effectiveness of new antiemetic medications versus traditional ones for preventing chemotherapy-induced nausea and vomiting (CINV) in patients undergoing moderate or highly emetogenic chemotherapy.
- It finds that novel agents like netupitant/palonosetron and olanzapine are at least as effective, if not better, than standard antiemetic treatments that use aprepitant and other agents.
- The study calls for more direct comparisons and larger trials to further understand the benefits of these new therapies in everyday clinical practice.
A multicenter, phase II trial of triplet antiemetic therapy with palonosetron, aprepitant, and olanzapine for highly emetogenic chemotherapy in breast cancer (PATROL-II).
Sci Rep
November 2024
Department of Clinical Pharmacology & Genetics, School of Pharmaceutical Sciences, University of Shizuoka, 52-1, Yada, Suruga-ku, Shizuoka, Shizuoka, 422-8002, Japan.
Article Synopsis
- Dexamethasone, commonly used to prevent nausea from chemotherapy, has side effects that prompt the search for alternatives without it.
- This study tested the efficacy and safety of palonosetron, aprepitant, and olanzapine in chemotherapy-naïve breast cancer patients, assessing their effectiveness in controlling nausea and vomiting.
- Results showed low total control rates (17.1%) for antiemetic therapies excluding dexamethasone, though olanzapine could be a viable replacement for patients unable to use dexamethasone.
Antiemetic medications for preventing chemotherapy-induced nausea and vomiting in children: a systematic review and Bayesian network meta-analysis.
Support Care Cancer
October 2024
Centre for Reviews and Dissemination, University of York, Heslington, York, YO10 5DD, UK.
Article Synopsis
- * A systematic review and Bayesian network meta-analysis (NMA) were conducted to compare multiple antiemetic treatments, analyzing data from 16 randomized controlled trials involving over 3,000 patients.
- * Results indicate that NK1 antagonists combined with ondansetron are the most effective option for preventing CINV in children, particularly when given with dexamethasone, while olanzapine also shows significant benefits when added to certain regimens.
Comparative effectiveness of netupitant-palonosetron plus dexamethasone versus aprepitant-based regimens in mitigating chemotherapy-induced nausea and vomiting: a meta-analysis of randomized controlled trials.
Oncologist
September 2024
Department of Nursing, Faculty of Medicine, Universitas Pendidikan Ganesha, Bali, Indonesia.
Background: Despite guidelines for managing chemotherapy-induced nausea and vomiting (CINV), there remains a need to clarify the optimal use of neurokinin-1 (NK1) receptor antagonists. Comparing the effectiveness of NEPA (netupitant-palonosetron) plus dexamethasone with other NK1 antagonist-based regimens combined with a 5HT3 receptor antagonist and dexamethasone is crucial for informed decision-making and improving patient outcomes.
Methods: We conducted a systematic review of the literature to assess randomized controlled trials (RCTs) comparing the efficacy, safety, and cost-effectiveness of NEPA plus dexamethasone and other NK1 antagonist-based regimens combined with a 5HT3 receptor antagonist and dexamethasone.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!